Product approval information is indicated for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/bOQWLRJ
No comments:
Post a Comment